VantroMarket Overview
← All markets
Health Market Overview

Spain

Last updated: November 2026
Regulatory Body
Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
Typical Timeline
90-210 days for national procedures; 210 days for centralised EMA procedures (with clock stops possible)
Regulatory Overview

The Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), operating under the Ministry of Health, is the primary national authority responsible for the regulation, authorisation, and post-market surveillance of pharmaceuticals, medical devices, in vitro diagnostics, and digital health solutions in Spain. The principal legislative framework includes Royal Decree-Law 1/2015 (consolidated text of the Guarantees and Rational Use of Medicines and Medical Devices Act), Royal Decree 1591/2009 on medical devices (now transitioning to EU MDR 2017/745), and Royal Decree 1662/2000 on IVDs (transitioning to EU IVDR 2017/746). Pharmaceuticals may be approved via the centralised procedure through the European Medicines Agency (EMA), the decentralised procedure, the mutual recognition procedure, or a purely national procedure, with AEMPS acting as reference or concerned member state. Medical devices and IVDs are subject to CE marking under the EU MDR and IVDR frameworks, with AEMPS overseeing market surveillance and Notified Bodies conducting conformity assessments.

For pharmaceutical submissions, applicants must use the Common Technical Document (CTD) format in electronic eCTD format, aligned with ICH guidelines. A local European Union representative or marketing authorisation holder established within the European Economic Area is mandatory. For medical devices, technical documentation must conform to Annex II and III of EU MDR/IVDR, and economic operators must register products in the European database EUDAMED. Spain has implemented Royal Decree 192/2023 to further align national device regulations with EU MDR timelines and strengthen post-market surveillance requirements. For digital health solutions, AEMPS published guidance in 2022 clarifying when software qualifies as a medical device under EU MDR Article 2(1), requiring CE marking where applicable. Recent reforms include accelerated access pathways such as the Cohesion Fund-backed conditional reimbursement schemes and the transposition of EU Joint Clinical Assessment (JCA) obligations under EU Regulation 2021/2282, which will progressively apply to oncology and advanced therapy products from 2025 onward.

Procurement Overview

Public procurement of health products in Spain operates within a decentralised framework, reflecting the country's system of 17 autonomous communities (comunidades autónomas), each of which manages its own health service (servicio de salud) and procurement budget. At the national level, the Ministry of Health coordinates policy, sets pricing and reimbursement conditions through the Interministerial Commission on Medicinal Product Prices (Comisión Interministerial de Precios de los Medicamentos, CIPM), and maintains the national formulary. Pharmaceuticals seeking public reimbursement must obtain a favourable resolution from the CIPM following a health technology assessment (HTA) conducted under the coordination of the RedETS network (Red Española de Agencias de Evaluación de Tecnologías Sanitarias). Medical devices and diagnostics are predominantly procured through regional tender processes governed by each autonomous community's health service, with centralised framework agreements available for high-volume commodities. Public procurement procedures comply with Law 9/2017 on Public Sector Contracts, which transposes EU Directives 2014/24/EU and 2014/25/EU, imposing transparency, open tender, and value-for-money criteria. Hospitals, whether public or publicly subsidised, must follow these procurement rules, and joint purchasing through regional central purchasing bodies (e.g., Servicio Madrileño de Salud or CatSalut in Catalonia) is increasingly common to leverage volume discounts.

The private healthcare sector in Spain is substantial, accounting for approximately 30% of total health expenditure, and operates through mutual insurance entities (mutualidades), private health insurers, and out-of-pocket payments. Private hospitals and clinics procure independently, negotiating directly with manufacturers and distributors without the price controls applicable to the public sector, though publicly reimbursed prices often serve as reference benchmarks. Spain is a high-income country and is not a primary recipient of donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, Gavi, or USAID health programmes; however, Spanish entities sometimes participate as donors or technical partners in these mechanisms. Local manufacturing preference policies are not formally codified in Spanish procurement law; however, EU-level strategic autonomy initiatives, including the European Health Emergency Preparedness and Response Authority (HERA) and the Important Projects of Common European Interest (IPCEI) on health, increasingly incentivise domestic or European manufacturing capacity, particularly for critical medicines, vaccines, and diagnostics. Manufacturers with local production or significant in-country economic contribution may benefit reputationally in tender evaluations, though price and quality criteria remain the primary determinants under current law.

Go deeper

This is a generic market overview. For a structured entry brief tailored to your product category, including regulatory pathway, pricing, and risk assessment, use the Market Brief tool.

Generate a free Market Brief for Spain →
Market overview generated by AI and updated monthly. Verify with in-country regulatory authorities before making market entry decisions.